PRISMA aims to validate a new kind of micropump tailored to drug delivery applications, achieving unparalleled accuracy, energy efficiency, and especially compactness.
To prove the viability of this technology in industrially relevant contexts, we will test the pump for its integration in wearable insulin delivery devices, one of the most challenging application scenarios for micro-pumps, also owning an excellent market potential.
By integrating Prisma in wearable devices, we aim to allow device manufacturers to realise extremely compact systems, more than 50 % more energy-efficient and, most importantly, 50 to 60 % more accurate in administering the dose combining these features with high reliability. In PRISMA, the extreme compactness of the pump relies on a new class of gigantic electrostrictors that are environmentally friendly and biocompatible. Such a functional material enables an innovative microcapillary geometry with nearly no "dead volume" in the device. The design would allow multidrug delivery systems, which in the diabetes industry turns into the much-lauded but still hard to realise multi-hormone treatment.
This project has received fundings from Horizont Europe – EIC Transition and will be running from 01-07-2022 to 30-06-2025.